

Manufacturer Name	NDC	Name of Prescription Drug	Strength	Pack Size/Volume	WAC (as of date of commercial availability)	Date of Commercial Availability	Estimated volume of patients who may be prescribed drug	Breakthrough therapy designation? (Y/N)	Priority Review? (Y/N)	Date and price of acquisition if the drug was not developed by the manufacturer else N/A	A description of the marketing and pricing plans used in the launch of the new drug
Cipla USA, Inc.	69097060473	Lenalidomide Capsules	2.5mg	28	\$20,157.36	4/11/2023	Information Not Publicly Available	Y	N	N/A	Information Not Publicly Available
Cipla USA, Inc.	69097038481	Lenalidomide Capsules	20mg	21	\$15,118.04	4/11/2023	Information Not Publicly Available	Y	N	N/A	Information Not Publicly Available